Cequa for dry eye launched in US

Sun Pharmaceutical Industries has announced the U.S. launch of Cequa for treatment of dry eye.

The topical cyclosporine ophthalmic solution 0.09% is delivered via nanomicellar technology, which is intended to result in improved tissue penetration. The product launch follows the publication of a phase 3 study that showed a statistically significant improvement in Schirmer’s score among dry eye patients treated with Cequa.

“The U.S. launch of Cequa, the third product in our growing ophthalmic portfolio, marks the availability of a truly innovative treatment option for patients with dry eye disease — an area with a high unmet medical need,” Abhay Gandhi, CEO of Sun Pharma North America, said in a press release. “As a higher concentration cyclosporine product than what is currently commercially available, delivered with NCELL technology, Cequa continues to demonstrate our leadership in creating novel formulations of proven medications.”

Sun Pharmaceutical Industries has announced the U.S. launch of Cequa for treatment of dry eye.

The topical cyclosporine ophthalmic solution 0.09% is delivered via nanomicellar technology, which is intended to result in improved tissue penetration. The product launch follows the publication of a phase 3 study that showed a statistically significant improvement in Schirmer’s score among dry eye patients treated with Cequa.

“The U.S. launch of Cequa, the third product in our growing ophthalmic portfolio, marks the availability of a truly innovative treatment option for patients with dry eye disease — an area with a high unmet medical need,” Abhay Gandhi, CEO of Sun Pharma North America, said in a press release. “As a higher concentration cyclosporine product than what is currently commercially available, delivered with NCELL technology, Cequa continues to demonstrate our leadership in creating novel formulations of proven medications.”